Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study

BACKGROUND AND PURPOSE: To evaluate the 1‐year effectiveness and tolerability of galcanezumab in real life and the prognostic indicators of persistent response. METHODS: High‐frequency episodic migraine (HFEM) and chronic migraine (CM) patients treated with galcanezumab who completed a 1‐year observ...

Descripción completa

Detalles Bibliográficos
Autores principales: Vernieri, Fabrizio, Brunelli, Nicoletta, Marcosano, Marilena, Aurilia, Cinzia, Egeo, Gabriella, Lovati, Carlo, Favoni, Valentina, Perrotta, Armando, Maestrini, Ilaria, Rao, Renata, d'Onofrio, Luigi, Finocchi, Cinzia, Aguggia, Marco, Bono, Francesco, Ranieri, Angelo, Albanese, Maria, Di Piero, Vittorio, Cevoli, Sabina, Altamura, Claudia, Barbanti, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Headache
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086852/
https://www.ncbi.nlm.nih.gov/pubmed/36097739
http://dx.doi.org/10.1111/ene.15563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086852/
https://www.ncbi.nlm.nih.gov/pubmed/36097739
http://dx.doi.org/10.1111/ene.15563

Ejemplares similares